Emory-GA Tech Nanotechnology Center for Personalized an*

Emory-GA Tech 纳米技术中心个性化*

• 批准号: 7497950
• 负责人: SHUMING NIE
• 金额: $ 360万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7497950
• 关键词: ALPP; American Cancer Society; Animals; Antibodies; Bioinformatics; Biological Markers; Biology; Biomedical Engineering; Biometry; Biopsy; Brain Neoplasms; Breast; Cancer Biology; Cancer Center; Caring; Centers for Disease Control and Prevention (U.S.); Class; Clinical; Clinical Oncology; Collaborations; Development; Disseminated Malignant Neoplasm; Education and Outreach; Gene Expression; Human; Incidence; Institutes; Investments; Large Intestine Carcinoma; Link; Lymphoma; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Medical Oncology; Metastatic Neoplasm to the Bone; Modeling; Molecular; Molecular Profiling; Nanotechnology; Neoplasm Metastasis; Numbers; Outcome; Pathology; Patients; Phenotype; Predisposition; Prostate; Quantum Dots; Reagent; Research; Signal Transduction Inhibitor; Signal Transduction Pathway; Specialized Program of Research Excellence; Specimen; Surface; Technology Assessment; Therapeutic Uses; Tissues; Translating; Translations; USA Georgia; Universities; Western Asia Georgia; anti-cancer therapeutic; anticancer research; biocomputing; bone; cancer cell; commercialization; concept; improved; malignant breast neoplasm; molecular imaging; mortality; nanomaterials; nanoparticle; nanoprobe; novel; oncology; tumor

This application proposes a cross-disciplinary Center of Cancer Nanotechnology Excellence (CCNE) at Emory University and Georgia Tech that will integrate nanotechnology with cancer biomolecular signatures (biomarkers) for personalized and predictive oncology. The overarching scientific focus is to accelerate the development of bioconjugated nanoparticles for cancer molecular imaging, molecular profiling, and personalized therapy. The proposed research will further develop new nanoparticle reagents for co-targeting signal transduction pathways and its microenvironments that are involved in bone metastasis. This research is broadly applicable to many types of malignant tumors such as lung cancer, colorectal carcinoma, ovarian cancer, brain tumors, and lymphomas; but proof of concept research is focused on human prostate and breast cancers and their clinically aggressive phenotypes - including interrogations of cancer cells and patient tissue biopsies. A compelling reason for this focus is that breast and prostate cancers represent a number of compelling challenges and opportunities in human oncology such as high incidence and mortality, evidence that targeted therapies can improve survival in these cancers, and our linkages to NCI Specialized Programs of Research Excellence (SPORE) in both prostate and breast cancers. The CCNE has 6 "synergistic projects" with crossdisciplinary teams, each with expertise in nanotechnology, bioengineering, clinical oncology, and basic cancer biology. Project #1 will develop quantum dots and targeted nanoparticles for cancer molecular imaging (Nie). Project #2 will develop novel molecular beacons and activatable nanoprobes for gene expression studies of single cancer cells (Bao). Project #3 will optimize and translate "nanotyping" multicolor sets of antibody linked quantum dots to multiplex cancer biomarkers that can predict clinical outcomes and susceptibility to signal transduction inhibitors in medical oncology (Simons/O'Regan). Project #4 will develop surface-enhanced Raman spectroscopic (SERS) nanotags and atomic nanoclusters for molecular profiling in cancer pathology (Natan/Young). Project #5 will develop nanoparticle anti-cancer therapeutics using a new class of self-assembled and biodegradable nanoparticles (Shin). Project #6 will focus on basic cancer metastasis biology and creation of new reagents via bioconjugated nanoparticles to target metastatic cancer cell clones and their bone stromal microenvironments (Chung). These projects are supported by 5 core functions: nanomaterials synthesis and fabrication (Core 1 - Z. Wang); biocomputing and bioinformatics (Core 2 - M. Wang); tissue specimens and animal tumor models (Core 3 - Datta); onconanotechnology education and outreach (Core 4 - Simons); and center administration, biostatistics support, technology assessment, and commercialization (Core 5 - Nie/Simons/Murdock). This CCNE is strengthened by collaborations with three NCI CCCs, investment from the Georgia Research Alliance, Georgia Cancer Coalition, and industrial partners. The CCNE is embedded in the Winship Cancer Institute, a new integrated 280K sq ft cancer research and care building, and has a special constellation of US partners, the American Cancer Society and the Centers for Disease Control, for accelerating the discovery and clinical translation of nanotechnology to reducing the burden of human cancer.

该申请提议在埃默里大学和佐治亚理工学院建立一个跨学科的癌症纳米技术卓越中心（CCNE），将纳米技术与癌症生物分子特征（生物标志物）相结合，以实现个性化和预测性肿瘤学。首要的科学重点是加速用于癌症分子成像、分子分析和个性化治疗的生物共轭纳米颗粒的开发。拟议的研究将进一步开发新的纳米颗粒试剂，用于共同靶向参与骨转移的信号转导途径及其微环境。该研究广泛适用于肺癌、结直肠癌、卵巢癌、脑瘤、淋巴瘤等多种恶性肿瘤；但概念验证研究的重点是人类前列腺癌和乳腺癌及其临床侵袭性表型，包括对癌细胞和患者组织活检的询问。这种关注的一个令人信服的原因是，乳腺癌和前列腺癌代表了人类肿瘤学中的许多引人注目的挑战和机遇，例如高发病率和死亡率，有证据表明靶向治疗可以提高这些癌症的生存率，以及我们与 NCI 前列腺癌和乳腺癌专业卓越研究计划 (SPORE) 的联系。 CCNE 有 6 个由跨学科团队组成的“协同项目”，每个项目都拥有纳米技术、生物工程、临床肿瘤学和基础癌症生物学方面的专业知识。项目#1将开发用于癌症分子成像的量子点和靶向纳米粒子（Nie）。项目#2 将开发新型分子信标和可激活纳米探针，用于单个癌细胞 (Bao) 的基因表达研究。项目＃3将优化和翻译“纳米分型”多色抗体组连接的量子点到多重癌症生物标志物，可以预测医学肿瘤学中的临床结果和对信号转导抑制剂的敏感性（Simons/O'Regan）。项目 #4 将开发表面增强拉曼光谱 (SERS) 纳米标签和原子纳米簇，用于癌症病理学中的分子分析 (Natan/Young)。项目 #5 将使用新型自组装和可生物降解的纳米颗粒 (Shin) 开发纳米颗粒抗癌疗法。项目 #6 将重点关注基础癌症转移生物学，并通过生物共轭纳米颗粒创建新试剂，以靶向转移性癌细胞克隆及其骨基质微环境 (Chung)。这些项目由 5 个核心功能支持：纳米材料合成和制造（核心 1 - Z. Wang）；生物计算和生物信息学（核心 2 - M. Wang）；组织标本和动物肿瘤模型（核心3 - Datta）； onconanotechnology 教育和推广（核心 4 - Simons）；中心管理、生物统计支持、技术评估和商业化（核心 5 - Nie/Simons/Murdock）。该 CCNE 通过与三个 NCI CCC 的合作、佐治亚研究联盟、佐治亚癌症联盟和工业合作伙伴的投资得到加强。 CCNE 位于温希普癌症研究所 (Winship Cancer Institute) 内，这是一栋占地 28 万平方英尺的新型综合癌症研究和护理大楼，并拥有美国癌症协会和疾病控制中心等特殊美国合作伙伴，致力于加速纳米技术的发现和临床转化，以减轻人类癌症的负担。